We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Conditions in the Tumor Microenvironment Change Role of p53

By LabMedica International staff writers
Posted on 09 Aug 2018
Print article
Image: The effects of p53 in cancer-associated fibroblasts on cancer cell migration: Cancer cells (magenta) migrate in the direction of cancer-associated fibroblasts (yellow) that express a non-mutated p53 gene (left); this migration slows down (center) when the p53 in the fibroblasts is silenced; when substances released by the cancer-associated fibroblasts are added to the laboratory dish, the migration is restored (right) (Photo courtesy of the Weizmann Institute of Science).
Image: The effects of p53 in cancer-associated fibroblasts on cancer cell migration: Cancer cells (magenta) migrate in the direction of cancer-associated fibroblasts (yellow) that express a non-mutated p53 gene (left); this migration slows down (center) when the p53 in the fibroblasts is silenced; when substances released by the cancer-associated fibroblasts are added to the laboratory dish, the migration is restored (right) (Photo courtesy of the Weizmann Institute of Science).
Cancer researchers have found that changes occurring in the tumor microenvironment manipulate the activity of fibroblast p53 protein, causing it to promote rather than restrict cancer growth.

Cancer cells coexist with noncancerous adjacent cells that constitute the tumor microenvironment and impact tumor growth through diverse mechanisms. In particular, cancer-associated fibroblasts (CAFs) promote tumor progression in multiple ways. Earlier studies have revealed that in in contrast to the situation in CAFs, p53 in normal fibroblasts (NFs) plays a tumor-suppressive role to restrict tumor growth.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) set out to study the role of p53 in CAFs. To carry out this research, they used a combination of cell culture and a cancer-carrying mouse model.

The investigators reported in the June 19, 2018, issue of the journal Proceedings of the National Academy of Sciences of the United States of America that the transcriptional program supported by p53 was altered substantially in CAFs relative to NFs. In agreement, the secretion of proteins dependent on p53 was also altered in CAFs. This transcriptional rewiring rendered p53 a significant contributor to the distinct intrinsic features of CAFs, as well as promoted tumor cell migration and invasion in culture.

The ability of CAFs to promote tumor growth in mice was greatly compromised by depletion of their endogenous p53. Furthermore, co-cultivation of NFs with cancer cells partially rendered their p53-dependent transcriptome to be more similar to that of CAFs.

The investigators concluded by saying, "Our findings raise the intriguing possibility that tumor progression may entail a nonmutational conversion (“education”) of stromal p53, from tumor suppressive to tumor supportive."

Related Links:
Weizmann Institute of Science

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.